Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
Autore:
Kosmas, C; Tsavaris, NB; Polyzos, A; Malamos, NA; Katsikas, M; Antonopoulos, MJ;
Indirizzi:
Helena Venizelou Hosp, Dept Med, Med Oncol Unit, Athens 16341, Greece Helena Venizelou Hosp Athens Greece 16341 col Unit, Athens 16341, Greece Univ Athens, Sch Med, Laikon Gen Hosp, Med Oncol Unit, GR-11527 Athens, Greece Univ Athens Athens Greece GR-11527 d Oncol Unit, GR-11527 Athens, Greece
Titolo Testata:
BRITISH JOURNAL OF CANCER
fascicolo: 2, volume: 82, anno: 2000,
pagine: 300 - 307
SICI:
0007-0920(200001)82:2<300:PISODP>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; CELL CARCINOMA; OVARIAN-CANCER; BREAST-CANCER; TRIAL; CYCLOPHOSPHAMIDE; INFUSION; TUMORS; CARBOPLATIN; RADIATION;
Keywords:
paclitaxel; ifosfamide; cisplatin; phase I study;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Kosmas, C Helena Venizelou Hosp, Dept Med, Med Oncol Unit, 21 Apolloniou St, Athens 16341, Greece Helena Venizelou Hosp 21 Apolloniou St Athens Greece 16341 eece
Citazione:
C. Kosmas et al., "Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours", BR J CANC, 82(2), 2000, pp. 300-307

Abstract

Based on the already known in vitro synergy between paclitaxel (taxol), cisplatin and oxazophosphorine cytostatics and the broad spectrum of activityof the above drugs we sought to evaluate the paclitaxel (taxol)-ifosfamide-cisplatin (PIC) combination in the outpatient setting in individuals with a variety of advanced solid tumours. Cohorts of patients were entered into six successive dose levels (DLs) with drug doses ranging as follows: paclitaxel 135-215 mg m(-2) day 1 - (1 h infusion), ifosfamide 4.5-6.0 g m(-2) (total dose) - divided over days 1 and 2, and cisplatin 80-100 mg m(-2) (total) - divided over days 1 and 2. Granulocyte colony-stimulating factor was given from day 5 to 14. Forty-two patients were entered. Eighteen patients had 2-8 cycles of prior chemotherapy with no taxanes or ifosfamide(cisplatinwas allowed). The regimen was tolerated with outpatient administration in 36/42 patients. Toxicities included: grade 4 neutropenia for less than or equal to 5 days in 27% of cycles; 5 episodes of febrile neutropenia in threepatients at DL-III, -V and -VI. Grade 3/4 thrombocytopenia and cumulative grade 3 anaemia were seen in 7% and 13% of cycles respectively. Three casesof severe grade 3 neuromotor/sensory neuropathy were recorded at DL-II, -III, and -V, all after cycle 3. The maximum tolerated dose was not formally reached at DL-V, but because of progressive anaemia and asthenia/fatigue, it was decided to test a new DL-VI with doses of paclitaxel 200 mg m(-2), ifosfamide 5.0 g m(-2) and cisplatin 100 mg m(-2) this appeared to be tolerable and is recommended for further phase II testing. The response rate was 47.5% (complete response + partial response: 20/42), The PIC regimen appearsto be feasible and safe in the outpatient setting. Care should he paid to neurotoxicity. Phase II studies are starting in non-small-cell lung cancer,ovarian cancer and head and neck cancer at DL-VI. (C) 2000 Cancer ResearchCampaign.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 06:41:28